Sun Pharma shares slump 7.5% on warning letter from USFDA

December 21, 2015 01:12 pm | Updated March 24, 2016 11:17 am IST - Mumbai

Shares of Sun Pharmaceutical slumped 7.5 per cent on Monday as the company has received a warning letter from the USFDA over violation of manufacturing norms at its facility at Halol in Gujarat.

The stock dipped 7.39 per cent to Rs. 732 on BSE. On NSE, it plunged 7.48 per cent to Rs. 731.

The stock was the top loser among the blue-chip Sensex and Nifty scrips. The warning letter follows inspection of the facility in September 2014 by U.S. Food and Drug Administration (USFDA) inspectors.

“Post the September 2014 inspection, the USFDA has withheld future product approvals from the Halol facility. This situation may continue until all issues are resolved. Sun Pharma expects to request a re-inspection by USFDA upon completion of its remediation commitments,” the company had said in a statement on Saturday.

“Sun Pharma will respond to this warning letter with a detailed plan within the stipulated time frame,” it said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.